Diffuse Large B-Cell Epstein-Barr Virus–Positive Primary CNS Lymphoma in Non-AIDS Patients: High Diagnostic Accuracy of DSC Perfusion Metrics

References

1. 1.↵
   1. Chiavazza C,
   2. Pellerino A,
   3. Ferrio F, et al

   . Primary CNS lymphomas: challenges in diagnosis and monitoring. Biomed Res Int 2018;2018:3606970 doi:10.1155/2018/3606970 pmid:30035121

   CrossRefPubMed
2. 2.↵
   1. Qian L,
   2. Tomuleasa C,
   3. Florian I-A, et al

   . Advances in the treatment of newly diagnosed primary central nervous system lymphomas. Blood Res 2017;52:159–66 doi:10.5045/br.2017.52.3.159 pmid:29043230

   CrossRefPubMed
3. 3.↵
   1. Bühring U,
   2. Herrlinger U,
   3. Krings T, et al

   . MRI features of primary central nervous system lymphomas at presentation. Neurology 2001;57:393–96 doi:10.1212/wnl.57.3.393 pmid:11515505

   CrossRefPubMed
4. 4.↵
   1. Malikova H,
   2. Koubska E,
   3. Weichet J, et al

   . Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma? Cancer Imaging 2016;16:40 doi:10.1186/s40644-016-0098-9 pmid:27894359

   CrossRefPubMed
5. 5.↵
   1. Mansour A,
   2. Qandeel M,
   3. Abdel-Razeq H, et al

   . MR imaging features of intracranial primary CNS lymphoma in immune competent patients. Cancer Imaging 2014;14:22 doi:10.1186/1470-7330-14-22 pmid:25608570

   CrossRefPubMed
6. 6.↵
   1. Haldorsen IS,
   2. Espeland A,
   3. Larsson EM

   . Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 2011;32:984–92 doi:10.3174/ajnr.A2171 pmid:20616176

   Abstract/FREE Full Text
7. 7.↵
   1. Tang YZ,
   2. Booth TC,
   3. Bhogal P, et al

   . Imaging of primary central nervous system lymphoma. Clin Radiol 2011;66:768–77 doi:10.1016/j.crad.2011.03.006 pmid:21513925

   CrossRefPubMed
8. 8.↵
   WHO Classification of Tumours Editorial Board. World Health Organization Classification of Tumours of the Central Nervous System. 5th ed. International Agency for Research on Cancer; 2021
9. 9.↵
   1. Sauter A,
   2. Faul C,
   3. Bitzer M, et al

   . Imaging findings in immunosuppressed patients with Epstein Barr virus-related B cell malignant lymphoma. AJR Am J Roentgenol 2010;194:141–49 doi:10.2214/AJR.09.3264 pmid:20093565

   CrossRefPubMed
10. 10.↵
    1. Lee HY,
    2. Kim HS,
    3. Park JW, et al

    . Atypical imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas in patients without AIDS. AJNR Am J Neuroradiol 2013;34:1562–67 doi:10.3174/ajnr.A3429 pmid:23413244

    Abstract/FREE Full Text
11. 11.↵
    1. Jiménez de la Peña M del M,
    2. Vicente LG,
    3. Alonso RC, et al

    . The multiple faces of nervous system lymphoma. Atypical magnetic resonance imaging features and contribution of the advanced imaging. Curr Probl Diagn Radiol 2017;46:136–45 doi:10.1067/j.cpradiol.2016.04.004 pmid:27475832

    CrossRefPubMed
12. 12.↵
    1. Lin X,
    2. Khan IRA,
    3. Seet YH, et al

    . Atypical radiological findings of primary central nervous system lymphoma. Neuroradiology 2020;62:669–76 doi:10.1007/s00234-020-02377-0 pmid:32077984

    CrossRefPubMed
13. 13.↵
    1. Shin DJ,
    2. Lee EJ,
    3. Lee JE, et al

    . Common and uncommon features of central nervous system lymphoma on traditional and advanced imaging modalities. Neurographics 2017;7:437–49 doi:10.3174/ng.9170229

    CrossRef
14. 14.↵
    1. Suh CH,
    2. Kim HS,
    3. Lee SS, et al

    . Atypical imaging features of primary central nervous system lymphoma that mimics glioblastoma: utility of intravoxel incoherent motion MR imaging. Radiology 2014;272:504–13 doi:10.1148/radiol.14131895 pmid:24697149

    CrossRefPubMed
15. 15.↵
    1. Swerdlow SH,
    2. Campo E,
    3. Pileri SA, et al

    . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375–90 doi:10.1182/blood-2016-01-643569 pmid:26980727

    Abstract/FREE Full Text
16. 16.↵
    1. Gandhi MK,
    2. Hoang T,
    3. Law SC, et al

    . EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood 2021;137:1468–77 doi:10.1182/blood.2020008520 pmid:33202420

    CrossRefPubMed
17. 17.↵
    1. Mahale P,
    2. Shiels MS,
    3. Lynch CF, et al

    . Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients. Am J Transplant 2018;18:453–61 doi:10.1111/ajt.14465 pmid:28805292

    CrossRefPubMed
18. 18.↵
    1. Verdu-Bou M,
    2. Tapia G,
    3. Hernandez-Rodriguez A, et al

    . Clinical and therapeutic implications of Epstein–Barr virus in HIV-related lymphomas. Cancers (Basel) 2021;13:5534 doi:10.3390/cancers13215534 pmid:34771697

    CrossRefPubMed
19. 19.↵
    1. Kaulen LD,
    2. Karschnia P,
    3. Dietrich J, et al

    . Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis. J Neurooncol 2020;149:153–59 doi:10.1007/s11060-020-03583-9 pmid:32683530

    CrossRefPubMed
20. 20.↵
    1. Mancuso S,
    2. Carlisi M,
    3. Santoro M, et al

    . Immunosenescence and lymphomagenesis. Immun Ageing 2018;15:22 doi:10.1186/s12979-018-0130-y pmid:30258468

    CrossRefPubMed
21. 21.↵
    1. Barosi G

    . An immune dysregulation in MPN. Curr Hematol Malig Rep 2014;9:331–39 doi:10.1007/s11899-014-0227-0 pmid:25139710

    CrossRefPubMed
22. 22.↵
    1. Pons-Escoda A,
    2. Garcia-Ruiz A,
    3. Naval-Baudin P, et al

    . Presurgical identification of primary central nervous system lymphoma with normalized time-intensity curve: a pilot study of a new method to analyze DSC-PWI. AJNR Am J Neuroradiol 2020;41:1816–24 doi:10.3174/ajnr.A6761 pmid:32943424

    Abstract/FREE Full Text
23. 23.↵
    1. Pons-Escoda A,
    2. Garcia-Ruiz A,
    3. Naval-Baudin P, et al

    . Voxel-level analysis of normalized DSC-PWI time-intensity curves: a potential generalizable approach and its proof of concept in discriminating glioblastoma and metastasis. Eur Radiol 2022;32:3705–15 doi:10.1007/s00330-021-08498-1 pmid:35103827

    CrossRefPubMed
24. 24.↵
    1. Lee MD,
    2. Baird GL,
    3. Bell LC, et al

    . Utility of percentage signal recovery and baseline signal in DSC-MRI optimized for relative CBV measurement for differentiating glioblastoma, lymphoma, metastasis, and meningioma. AJNR Am J Neuroradiol 2019;40:1445–50 doi:10.3174/ajnr.A6153 pmid:31371360

    Abstract/FREE Full Text
25. 25.↵
    1. Xing Z,
    2. You RX,
    3. Li J, et al

    . Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Clin Neuroradiol 2014;24:329–36 doi:10.1007/s00062-013-0255-5 pmid:23994941

    CrossRefPubMed
26. 26.↵
    1. Neska-Matuszewska M,
    2. Bladowska J,
    3. Sąsiadek M, et al

    . Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone: searching for a practical approach. PLoS One 2018;13:e0191341 doi:10.1371/journal.pone.0191341 pmid:29342201

    CrossRefPubMed
27. 27.↵
    1. Wang S,
    2. Kim S,
    3. Chawla S, et al

    . Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2011;32:507–14 doi:10.3174/ajnr.A2333 pmid:21330399

    Abstract/FREE Full Text
28. 28.↵
    1. Lee IH,
    2. Kim ST,
    3. Kim HJ, et al

    . Analysis of perfusion weighted image of CNS lymphoma. Eur J Radiol 2010;76:48–51 doi:10.1016/j.ejrad.2009.05.013 pmid:19500931

    CrossRefPubMed
29. 29.↵
    1. Calli C,
    2. Kitis O,
    3. Yunten N, et al

    . Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 2006;58:394–403 doi:10.1016/j.ejrad.2005.12.032 pmid:16527438

    CrossRefPubMed
30. 30.↵
    1. Mangla R,
    2. Kolar B,
    3. Zhu T, et al

    . Percentage signal recovery derived from MR dynamic susceptibility contrast imaging is useful to differentiate common enhancing malignant lesions of the brain. AJNR Am J Neuroradiol 2011;32:1004–10 doi:10.3174/ajnr.A2441 pmid:21511863

    Abstract/FREE Full Text
31. 31.↵
    1. Boxerman JL,
    2. Schmainda KM ,
    3. Weisskoff RM

    . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67 pmid:16611779

    PubMedWeb of Science
32. 32.↵
    1. Cha S,
    2. Lupo JM,
    3. Chen MH, et al

    . Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007;28:1078–84 doi:10.3174/ajnr.A0484 pmid:17569962

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Corn BW,
    2. Marcus SM,
    3. Topham A, et al

    . Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 1997;79:2409–13 pmid:9191531

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Kadan-Lottick NS,
    2. Skluzacek MC,
    3. Gurney JG

    . Decreasing incidence rates of primary central nervous system lymphoma. Cancer 2002;95:193–202 doi:10.1002/cncr.10643 pmid:12115333

    CrossRefPubMedWeb of Science
35. 35.↵
    1. De Robles P,
    2. Fiest KM,
    3. Frolkis AD, et al

    . The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol 2015;17:776–83 doi:10.1093/neuonc/nou283 pmid:25313193

    CrossRefPubMed
36. 36.↵
    1. Adachi K,
    2. Yamaguchi F,
    3. Node Y, et al

    . Neuroimaging of primary central nervous system lymphoma in immunocompetent patients: comparison of recent and previous findings. J Nippon Med Sch 2013;80:174–83 doi:10.1272/jnms.80.174 pmid:23832401

    CrossRefPubMed
37. 37.↵
    1. Wang ZD,
    2. Liu HH,
    3. Ma ZX, et al

    . Toxoplasma gondii infection in immunocompromised patients: a systematic review and meta-analysis. Front Microbiol 2017;8:1–12 doi:10.3389/fmicb.2017.00389] pmid:28197127

    CrossRefPubMed
38. 38.↵
    1. Arendt G,
    2. Maschke M

    . Update: opportunistic infections of the central nervous system in patients with iatrogenic immunosuppression: an update. Neurology International Open 2017;1:E316–25 doi:10.1055/s-0043-118924

    CrossRef
39. 39.↵
    1. Morollón N,
    2. Rodríguez F,
    3. Duarte J, et al

    . Brain lesions in a long-term kidney transplant recipient: primary cerebral lymphoma or cerebral toxoplasmosis? Neurologia 2017;32:268–70 doi:10.1016/j.nrleng.2015.06.016 pmid:26383060

    CrossRefPubMed
40. 40.↵
    1. Cindil E,
    2. Sendur HN,
    3. Cerit MN, et al

    . Validation of combined use of DWI and percentage signal recovery-optimized protocol of DSC-MRI in differentiation of high-grade glioma, metastasis, and lymphoma. Neuroradiology 2021;63:331–42 doi:10.1007/s00234-020-02522-9 pmid:32821962

    CrossRefPubMed